Back to the search results

Evangelisches Klinikum Bethel gGmbH Standort Bethel

Kantensiek 11
33617 Bielefeld

Phone: 0521-772-77000
Fax: 0521-772-78013
Mail: ed.bkve@ofni

  • Number of beds: 1.040
  • Number of specialist departments: 18
  • Number of inpatient cases: 27.716
  • Number of partial inpatient cases: 2.285
  • Number of outpatient cases: 72.971
  • Number of cases of inpatient-equivalent psychiatric treatment (StäB): 175
  • Hospital owners: Evangelische Klinikum Bethel gGmbH
  • Type of provider: freigemeinnützig
  • University Hospital
  • Academic teaching hospital
External comparative quality assurance
Further information
  • External quality assurance according to state law
    No participation
Chronische obstruktive Lungenerkrankung (COPD)

Quantity performed 71
Exception? No exception
Overall result forecast presentation: yes
Quantity performed reporting year: 71
Quantity forecast year: 61
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 44
Quantity forecast year: 47
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 72
Quantity forecast year: 74
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
No. Explanation
CQ01 Quality assurance measures for inpatient care with the indication abdominal aortic aneurysm
CQ02 Quality assurance measures for the inpatient care of children and adolescents with haemato-oncological diseases
CQ05 Measures for quality assurance in the care of pre-term and full-term neonates – Perinatal Centre LEVEL 1
CQ26 Decision on measures for quality assurance of targeted lung denervation by catheter ablation in chronic obstructive pulmonary disease
  • Clarifying chat completed: no
  • Clarifying chat not completed: no
  • No participation in clarifying chat: no
  • Notification of non-fulfilment of nursing care not made: yes
Number Group
309 Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
192 Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
153 Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations
* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

According to Section 4 (2) of the Quality Management Guideline, facilities must provide for the prevention of and intervention in cases of violence and abuse as part of their internal quality management. The aim is to prevent, recognise and respond appropriately to abuse and violence, particularly against vulnerable patient groups such as children and adolescents or people in need of help, and also to prevent it within the facility. The respective procedure is aligned with the size of the facility, the range of services and the patients in order to define customised solutions for sensitising the teams as well as other suitable preventative and interventional measures. These may include information materials, contact addresses, training/education, codes of conduct, recommendations for action/intervention plans or comprehensive protection concepts.

Gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie haben sich Einrichtungen, die Kinder und Jugendliche versorgen, gezielt mit der Prävention von und Intervention bei (sexueller) Gewalt und Missbrauch bei Kindern und Jugendlichen zu befassen (Risiko- und Gefährdungsanalyse) und – der Größe und Organisationsform der Einrichtung entsprechend – konkrete Schritte und Maßnahmen abzuleiten (Schutzkonzept). In diesem Abschnitt geben Krankenhäuser, die Kinder und Jugendliche versorgen, an, ob sie gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie ein Schutzkonzept gegen (sexuelle) Gewalt bei Kindern und Jugendlichen aufweisen.
  • Drug commission

Verfahrensanweisung Umgang mit Arzneimittel

08.09.2021

  • Zubereitung von TPE, Zytostatika durch St. Elisabeth-Apotheke Gütersloh
  • Elektronisches Apothekenbestellsystem, sowie elektronische Kurvenführung
  • Fallbesprechungen
  • Maßnahmen zur Vermeidung von Arzneimittelverwechslung
  • Spezielle AMTS-Visiten (z. B. pharmazeutische Visiten, antibiotic stewardship, Ernährung)
  • Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)
  • Aushändigung von arzneimittelbezogenen Informationen für die Weiterbehandlung und Anschlussversorgung der Patientin oder des Patienten im Rahmen eines (ggf. vorläufigen) Entlassbriefs
  • Aushändigung des Medikationsplans
  • VA zum Entlassmanagement, Mitgabe von BMP
The instruments and measures to promote drug therapy safety are presented with a focus on the typical procedures of the medication process in inpatient patient care. A special feature of the medication process in the inpatient environment is the transition management during admission and discharge. The instruments and measures listed below address structural elements, e.g. special IT equipment and work materials, as well as process aspects, such as work descriptions for particularly risky process steps or concepts for securing typical risk situations . In addition, proven measures to avoid or learn from medication errors can be specified. The hospital presents here which aspects it has already dealt with and which measures it has specifically implemented. The following aspects can be presented, if necessary using free text fields:
- Admission to hospital, including anamnesis
; Instruments and measures are presented for determining the old medication (drug history), the subsequent clinical assessment and the switch to the medication available in the hospital (house list), as well as for documenting both the patient's original medication and that for hospital treatment adapted medication.
- Medication process in the hospital
In this context, the following sub-processes are assumed as examples: drug history - prescription - patient information - drug delivery - drug use - documentation - therapy monitoring - result assessment. Instruments and measures for safe medication prescription can be presented, e.g. B. in terms of readability, clarity and completeness of the documentation, but also in terms of area of ​​application, effectiveness, benefit-risk ratio, tolerability (including potential contraindications, interactions, etc.) and resource considerations. Information can also be provided to support reliable medication ordering, delivery and use or administration.
- Discharge
In particular, the measures taken by hospitals can be presented to ensure that information on drug therapy is structured and passed on to doctors and physicians providing further treatment, as well as the appropriate provision of patients with drug information, medication plans and medications. Drug prescriptions are made.
AMTS is the totality of measures to ensure an optimal medication process with the aim of reducing medication errors and thus avoidable risks for patients during drug therapy. A prerequisite for the successful implementation of these measures is that AMTS is practised as an integral part of daily routine in an interdisciplinary and multi-professional approach.
Job
Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Training in other healing professions
Comment

Comment

Comment

In Kooperation mit der FH Bielefeld

Comment

Comment

Comment

Comment

Comment

Comment

Gesundheits- und Krankenpflegeassistentin, Gesundheits- und Krankenpflegeassistent

Comment

Comment

Comment

In Kooperation mit dem Studieninstitut Westfalen-Lippe

Michael Barenberg

Patientenfürsprecher

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-75070
Mail: ed.bkve@eniltoh

Paul Siebold

Patientenfürsprecher

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-75070
Mail: ed.bkve@eniltoh

Kira Stracke

Leitung Stabstelle Qualitäts- und Risikomanagement

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-77777
Mail: ed.bkve@eniltoh

Kira Stracke

Leitung Stabsstelle Qualitätsmanagement / Risikomanagement

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-79333
Mail: ed.bkve@ekcarts.arik

Priv.-Doz. Dr. med. Christian A. Jantos

Chefarzt des Instituts für Laboratoriumsmedizin, Mikrobiologie und Hygiene

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-79201
Mail: ed.bkve@sotnaj.naitsirhc

Dr. Annika Hilgers

Leitende Apothekerin (Dr. rer. medic.; M.Sc.)

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-78939
Mail: ed.bkve@sreglih.akinna

Petra Krause

Pflegedirektorin, Gesamtleitung Gesundheitsschulen

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-79841
Mail: ed.bkve@esuark.artep

Kantensiek 11
33617 Bielefeld

Phone: 0521-772-77000
Fax: 0521-772-78013
Mail: ed.bkve@ofni

Petra Krause

Pflegedirektorin

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-79841
Mail: ed.bkve@esuark.artep

Dr. Jens-Torge Meyer

Kaufmännischer Direktor Direktorium B

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-77011
Mail: ed.bkve@reyem.egrot-snej

Mathias Kreft

Geschäftsführer

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-79001
Mail: ed.bkve@tferk.saihtam

Prof. Dr. med. Thomas Vordemvenne

Chefarzt

Kantensiek 11
33617 Bielefeld

Phone: 0521 -772-77418
Mail: ed.bkve@ennevmedrov.samoht

IK: 260570044

Location number: 773641000

Old location number: 773641000